Rapt Therapeutics

Gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program Enables Bristol-Myers Squibb to fully explore the potential of IDO/TDO targeted immunotherapies in combination with its immuno-oncology portfolio NEW YORK & SAN CARLOS, Calif.–(

Brian Wong, M.D., Ph.D., joins as Chief Executive Officer and William Ho, M.D., Ph.D., joins as Chief Medical Officer Dual mechanism of FLX925 holds promise for the treatment of hematological malignancies, including acute myeloid leukemia associated with mutant FLT3 and CDK4/6 SOUTH SAN FRANCISCO,

Rekha Hemrajani joins as Chief Operating Officer SOUTH SAN FRANCISCO, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today that it has appointed Rekha Hemrajani as Chief

Paul Kassner, Ph.D., Joins as Vice President, Quantitative Biology and David Wustrow, Ph.D., Joins as Vice President, Drug Discovery SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer

RAPT Therapeutics develops therapeutics targeting key drivers of the immune system to treat inflammatory and immunologic diseases.

RAPT’s privacy policy covers information submitted or collected on the RAPT Site and states that RAPT is not responsible for the privacy practices of third-party websites linked from the site.